$ZTS · Zoetis Inc.
Zoetis filed its 10-Q for the quarter ended September 30, 2026. Revenue declined 1.3% year-over-year to $2.391B, while net income attributable to Zoetis fell to $591M from $721M a year earlier. GAAP diluted EPS was $1.44 versus $1.63, and adjusted EPS was $1.75. U.S. segment revenue decreased 6% to $1.246B, driven by an $89M decline in companion animal products, partially offset by a $13M livestock increase; international revenue rose 4% to $1.116B.
- Revenue fell 1.3% YoY to $2.391B in Q3 FY2026.
- Net income attributable to Zoetis dropped 18% to $591M from $721M.
- GAAP diluted EPS was $1.44, down from $1.63 a year ago.
- U.S. segment revenue fell 6% to $1.246B on softer companion animal demand.
- Restructuring and certain significant items rose to $43M in Q3 from $4M a year earlier.
Shares fell 6.87% to $83.07 in the regular session, with a modest -0.57% move since filing time, reflecting a negative reaction to the revenue decline and U.S. weakness.
Zoetis's core U.S. companion animal franchise is contracting, dragging overall revenue and earnings lower despite international growth.
Zoetis's U.S. companion animal softness contrasts with 4% international growth, highlighting divergent demand across animal-health end markets.
Softer U.S. companion animal end-market demand drove an $89M revenue decline, and restructuring charges plus certain significant items jumped to $43M in Q3 from $4M a year earlier.